Ascelia Pharma: Secures full support from the completed Rights Issue - Redeye

The preliminary result is 100% support and a gross proceed of SEK 105m. This outcome also adds future support from warrants due in spring 2025, adding SEK 30m gross (based on today’s share price). Ascelia Pharma (Ascelia) expects to confirm the outcome on 5 September. The preliminary result is distinctly positive for Ascelia as it reduces the financial uncertainty and allows Ascelia to proceed with Orviglance’s FDA submission process and advance discussion with future commercial partners ahead of the launch.

Länk till analysen i sin helhet: https://www.redeye.se/research/1038589/ascelia-pharma-secures-full-support-from-the-completed-rights-issue?utm_source=finwire&utm_medium=RSS